TICKERNERD
Menu
KVUEKVUEConsumer Defensive · Household & Personal Products

KVUE Stock Forecast: Kenvue, Inc. Price Predictions for 2026-2027

Last close, 3 Sept 2026
$19
−0.94% on the day

The 14 Wall Street analysts covering Kenvue, Inc. hold a median 12-month price target of $19 — +0.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 2 Sept 2026 — in the upper half.

Market cap
$36.7B
Ticker Nerd rank
65 / 100
Median analyst target
$19
Analysts covering
14
Revenue$4.0B+3.0% y/y
Operating income$758.0M
Net income$456.0M
Free cash flow$624.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.3%
1M
+0.8%
YTD
+13.7%
1Y
−2.9%
From 52W high
−3.4%
From 52W low
+40.7%
$13
$20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KVUE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kenvue, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 2 Sept 2026
65 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
86
Issuance
79
Value
78
Quality
64
Momentum
60
Growth
58
Accruals
53
Revisions
51
Size
7

Volatility (86): The share price has been relatively steady.

Revisions (51): Analysts have, on balance, been cutting their forecasts.

Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KVUE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KVUE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$14$16$18$20$22$24Oct 25Jan 26Apr 26Jul 26KVUEHigh $23Median $19Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
2 Buy12 Hold0 Sell
Low $18Median $19High $23

The green dot is the last close — the median target sits +0.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
11 Aug 2026UBSMaintainsNeutral$20 → $19
21 July 2026BarclaysMaintainsEqual-Weight$18 → $19
21 July 2026BarclaysMaintainsEqual-Weight—
16 July 2026UBSMaintainsNeutral$18 → $20
16 July 2026UBSMaintainsNeutral—
15 Apr 2026CitigroupMaintainsNeutral$20 → $19
15 Apr 2026CitigroupMaintainsNeutral—
14 Apr 2026BarclaysMaintainsEqual-Weight$19 → $18
14 Apr 2026BarclaysMaintainsEqual-Weight—
7 Apr 2026UBSMaintainsNeutral—
6 Mar 2026BarclaysMaintainsEqual-Weight—
18 Feb 2026Canaccord GenuityMaintainsHold—
18 Feb 2026CitigroupMaintainsNeutral—
18 Feb 2026UBSMaintainsNeutral—
30 Jan 2026JefferiesDowngradeHold—
10 Nov 2025BarclaysMaintainsEqual-Weight—
29 Oct 2025Canaccord GenuityDowngradeHold—
27 Oct 2025JefferiesMaintainsBuy—
10 Oct 2025JP MorganMaintainsOverweight—
9 Oct 2025CitigroupMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KVUE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

KVUE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 3 Sept 2026, Kenvue, Inc. returned −2.9% against +21.4% for the S&P 500, dividends included.

KVUE vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Oct 25Jan 26Apr 26Jul 26KVUES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KVUE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.6%
Analysts raising
1
Analysts cutting
8
Fundamentals

Kenvue, Inc. (KVUE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
22.5×

Cheaper than 34% of US stocks

Price / sales
2.4×

Cheaper than 48% of US stocks

Price / book
3.5×

Cheaper than 30% of US stocks

EV / EBITDA
12.7×

Cheaper than 29% of US stocks

Growth & margins
Revenue growth (YoY)
3.0%

Higher than 34% of US stocks

Earnings growth (YoY)
8.6%

Higher than 46% of US stocks

Gross margin
58.2%

Higher than 72% of US stocks

Operating margin
19.4%

Higher than 79% of US stocks

Net margin
10.8%

Higher than 71% of US stocks

Returns & dividend
Return on equity
15.6%

Higher than 75% of US stocks

Return on assets
7.0%

Higher than 85% of US stocks

Dividend yield
4.4%

Higher than 80% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Kenvue, Inc. (KVUE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Kenvue, Inc. has a market value of $36.7B and an enterprise value of $44.2B.

  • Revenue in the twelve months to 30 June 2026: $15.4B. The latest quarter grew 3.0% year on year.

  • Net income over the same four quarters: $1.7B, a 10.8% net margin.

  • Diluted earnings per share, trailing twelve months: $0.87.

  • Free cash flow in the twelve months to 30 June 2026: $1.9B.

  • Kenvue, Inc. spent $70.0M on share buybacks and $1.6B on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 1.9B.

  • Trailing P/E: 22.5×; forward P/E: 15.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 4.39%, paying out 98% of earnings.

  • Kenvue, Inc. employs 21,780 people — $707K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 3 Sept 2026

Data provided by Twelve Data

Peers

KVUE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHousehold & Personal Products
CompanyMarket capTKN rank
KVUEKenvue, Inc.$36.7B
65
KMBKimberly-Clark Corp.$36.3B
64
ELThe Estée Lauder Companies, Inc.$35.3B
84
CHDChurch & Dwight Co., Inc.$24.2B
70
CLColgate-Palmolive Co.$72.6B
96
CLXThe Clorox Co.$11.5B
30
ELFe.l.f. Beauty, Inc.$6.4B
38

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kenvue, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KVUE news & analysis

Australia clears Kimberly-Clark's acquisition of Kenvue but requires Carefree, Stayfree divestment

Reuters · 2 Sept 2026neutral

Australia's competition regulator has approved Kimberly-Clark's proposed $40 billion acquisition of Kenvue, on the condition that Kenvue's Carefree and Stayfree period care brands in the country be divested to address competition concerns.

Why it matters — The approval marks a key regulatory milestone for the Kimberly-Clark acquisition of Kenvue, though it requires divesting certain period care brands in Australia.

Kimberly-Clark seeks EU approval for $40 billion Kenvue deal

Reuters · 28 Aug 2026neutral

Kimberly-Clark has asked EU regulators for approval of its proposed $40 billion takeover of Tylenol maker Kenvue, as shown in documents on the European Commission's website.

Why it matters — A Kenvue watcher would care because the landmark deal's regulatory review marks a key procedural step shaping the company's ownership and future.

Best Dividend Kings: August 2026

Seeking Alpha · 24 Aug 2026neutral

An August 2026 Seeking Alpha report notes Dividend Kings are outperforming the S&P 500 YTD with a 14.98% total return versus SPY's 12.89%. It adds that 30 Dividend Kings are beating SPY, 25 appear potentially undervalued with 10% or higher annualized return potential, and that dividend growth among Kings accelerated to a 4.12% average rate with several notable increases announced.

Why it matters — KVUE watchers may follow this as context on Dividend King performance and dividend-growth trends, though Kenvue is not mentioned in the report.

Kimberly-Clark Appoints Suzana Blades as Senior Vice President and General Counsel

PRNewsWire · 13 Aug 2026neutral

Kimberly-Clark appointed Suzana Blades as Senior Vice President and General Counsel, effective September 1, 2026, reporting to Jeff Melucci and joining the Executive Leadership Team.

Why it matters — KVUE watchers may track competitor Kimberly-Clark's leadership changes as part of broader industry context.

Kenvue Q2 Deep Dive: Assessing Financial Metrics & Growth Prospects

Zacks Investment Research · 12 Aug 2026neutral

Kenvue's (KVUE) second-quarter sales and earnings missed estimates, but the company reported improved organic growth as Skin Health and Beauty segments led a broader recovery.

Why it matters — KVUE watchers would care because the results show a mixed quarter—missing estimates yet signalling momentum in organic growth with strong performance from key segments.

FAQ

Frequently asked questions about KVUE stock

What is the KVUE stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Kenvue, Inc. have a median 12-month price target of $19, with estimates ranging from $18 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KVUE stock a buy right now?

Of the 14 analysts covering Kenvue, Inc., 2 rate it a Buy, 12 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kenvue, Inc. 65 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KVUE?

As at 2 Sept 2026, Kenvue, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (86 of 100).

Will KVUE stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +0.3% from the last close, and Ticker Nerd's factor model ranks Kenvue, Inc. 65 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KVUE stock forecast for 2030?

No analyst covering Kenvue, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KVUE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $23 over the next 12 months.

How has KVUE stock performed over the past year?

Kenvue, Inc. returned -2.9% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kenvue, Inc. do?

Kenvue Inc. is a consumer health company focused on everyday care products across self care, skin health and beauty, and essential health.

What is the latest news on KVUE?

The most recent item we track (Reuters, 2 Sept 2026): "Australia clears Kimberly-Clark's acquisition of Kenvue but requires Carefree, Stayfree divestment". Australia's competition regulator has approved Kimberly-Clark's proposed $40 billion acquisition of Kenvue, on the condition that Kenvue's Carefree and Stayfree period care brands in the country be divested to address competition concerns.

Company

About Kenvue, Inc.

Kenvue Inc. is a consumer health company focused on everyday care products across self care, skin health and beauty, and essential health. Kenvue’s portfolio includes well-known brands such as Tylenol, Neutrogena, Aveeno, Listerine, Johnson’s, BAND-AID Brand, Zyrtec, and Nicorette, serving needs in pain relief, cough and allergy care, skincare, oral care, baby care, wound care, and smoking cessation. The company sells products to consumers and healthcare professionals across North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. As a pure-play consumer health business, Kenvue plays a significant role in the global over-the-counter and personal care markets, combining science-backed formulations with mass-market brand recognition.

CEO Mr. Kirk L. Perry · 21,780 employees · United States · https://www.kenvue.com